CERUS CORP

Analysis for Ticker: CERS

Cerus Corp is a company focused on keeping the blood supply safe by using special technology to kill germs in blood. The business is a machine designed to move money from regular people to banks and insiders while the company itself runs out of time. On 01/05/2026, the firm is trapped under 84,8$ million in total debt while its most important source of government cash, a contract with BARDA, is set to expire in 09/2026. The math is a disaster because the grace period on their loans has ended, and they must pay back 24,3$ million in hard cash before the year is over. Even though the stock price is 2,60$, giving the company a 514,0$ million market size, the business is burning through millions of dollars to pay for high-interest loans and free stock for its bosses while its profit margins are collapsing. The crisis grew from years of failure that created an accumulated deficit of 1.081,1$ million, which means the company has lost over one billion dollars since it began. To keep going, Cerus Corp became a servant to its debt and its suppliers. They borrowed 65,0$ million and another 20,0$ million from MidCap Financial Trust at interest rates as high as 11,1%, which bleeds out 8,3$ million a year just in interest. They also gave total control of their production to Fresenius Kabi AG until 2031, a sole supplier that has the power to raise prices and shrink the company's profits. In 2025, Cerus Corp paid Fresenius 93,8$ million for supplies while losing 15,6$ million overall. They spent 67,7$ million on research for a new red blood cell system that has been rejected by regulators like the Dutch Medicines Evaluation Board, TÜV-SÜD, and French health agencies. While the company bled, the board gave the bosses 22,8$ million in free stock in 2025 alone.